Article Text

Download PDFPDF
Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas
  1. C. B. de Campos, DVM MSc1,
  2. G. E. Lavalle, DVM MSc PhD3,
  3. S Fialho Ligório, BSc MSc PhD4,
  4. F. Camargo Nunes, DVM MSc PhD2,
  5. R. A. Carneiro, DVM MSc PhD3,
  6. R. L. Amorim, DVM MSc PhD5 and
  7. G. D. Cassali, DVM MSc PhD2
  1. 1Department of Veterinary Clinic and Surgery, School of Agricultural and Veterinary Sciences of the Sao Paulo State University (FCAV/UNESP) – Jaboticabal Campus, Jaboticabal, Brazil
  2. 2Laboratory of Comparative Pathology, Department of General Pathology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
  3. 3Department of Veterinary Clinic and Surgery, Veterinary School, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
  4. 4Department of Pharmaceutical and Biotechnological Development, Fundação Ezequiel Dias, Belo Horizonte, Brazil
  5. 5Department of Veterinary Clinics, College of Veterinary Medicine and Animal Science, Sao Paulo State University (FMVZ/UNESP) – Botucatu Campus, Botucatu, Brazil
  1. E-mail for correspondence: cassalig{at}


The aim of the study was to evaluate the incidence of adverse events (AEs) in female dogs diagnosed with advanced clinical stage mammary gland neoplasms following treatment with thalidomide. A prospective analysis of 29 female dogs treated with a high dose (HD) of 20 mg/kg/day of thalidomide for three months followed by a low dose (LD) of 10 mg/kg/day of thalidomide for three months was performed. All patients underwent physical examination, complete blood count, serum biochemistry profile, thoracic radiographs, and abdominal ultrasound analysis before the treatment and after the HD and LD. Clinical AEs were absent in 16/29 (55.17 per cent) patients following HD. An initial 3–5 day period of somnolence was described in 4/29 (13.79 per cent), prolonged somnolence in 5/29 (17.24 per cent), a short period of somnolence lasting only a few hours in 3/29 (10.34 per cent), and difficulty to rouse was described in 5/29 (17.24 per cent) cases. Two patients (6.89 per cent) presented with prolonged somnolence that interfered with activities of daily living, resulting in anticipation of the dose reduction to the proposed LD after 15 days of the HD treatment. Following dose reduction, AE improvement was observed in all patients. Albeit remaining within the reference ranges, erythrocytes, haematocrit, total leucocyte count, neutrophils, lymphocytes, monocytes and γ-glutamyltranspeptidase showed significant alteration associated to thalidomide treatment.

  • Oncology
  • Dogs
  • Mammary gland
  • Adverse events
  • Thalidomide
View Full Text

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.